Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan-peptide association complex (Rumalon)

David D. Dean, Ofelia E. Muniz, Ivette Rodriquez, Manuel R. Carreno, Sara Morales, Agueda Agundez, Maria Elena Madan, Roy D Altman, Marlieseo Annefeld, David S. Howell

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The chondroprotective potential of glycosaminoglycan-peptide association complex (GP-C) was examined in the medial meniscectomy model of lapine osteoarthritis (OA). Prophylactic treatment with increasing doses of intramuscular GP-C (0.05-0.5 ml/kg) caused a significant reduction in OA lesion area and histologic scores, and the effect on disease activity appeared to be dose related. The DNA and uronic acid contents of OA tissue were unaffected by prophylactic treatment with GP-C. However, levels of hydroxyproline in OA cartilage ineased to near control levels with prophylactic treatment. Cartilage levels of active and total metalloproteinases that digest proteoglycans were elevated in rabbits with OA; prophylactic treatment with low-dose GP-C (0.05 ml/kg) produced a significant reduction in active, but not total, enzyme. Cartilage levels of tissue inhibitor of metalloproteinases in animals with OA were comparable with control levels, but rose with increasing doses of GP-C. We also investigated GP-C as a therapeutic treatment in animals that had already developed OA lesions. Carbon black retention and histologic score returned to near-normal after therapeutic treatment with GP-C. Uronic acid and hydroxyproline levels were decreased in OA cartilage. Therapeutic treatment with GP-C had no statistically significant effect on uronic acid levels, but was associated with increased hydroxyproline content in the cartilage. The changes in metalloproteinase and metalloproteinase inhibitor were similar to those found in the studies of prophylactic treatment. The findings in this animal model may help explain some of the beneficial effects of GP-C in human OA.

Original languageEnglish (US)
Pages (from-to)304-313
Number of pages10
JournalArthritis and Rheumatism
Volume34
Issue number3
StatePublished - Mar 1991

Fingerprint

Glycosaminoglycans
Osteoarthritis
Peptides
Cartilage
Uronic Acids
Hydroxyproline
Metalloproteases
Soot
Rumalon
Tissue Inhibitor of Metalloproteinases
Proteoglycans
Therapeutics
Animal Models
Rabbits
DNA
Enzymes

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Dean, D. D., Muniz, O. E., Rodriquez, I., Carreno, M. R., Morales, S., Agundez, A., ... Howell, D. S. (1991). Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan-peptide association complex (Rumalon). Arthritis and Rheumatism, 34(3), 304-313.

Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan-peptide association complex (Rumalon). / Dean, David D.; Muniz, Ofelia E.; Rodriquez, Ivette; Carreno, Manuel R.; Morales, Sara; Agundez, Agueda; Madan, Maria Elena; Altman, Roy D; Annefeld, Marlieseo; Howell, David S.

In: Arthritis and Rheumatism, Vol. 34, No. 3, 03.1991, p. 304-313.

Research output: Contribution to journalArticle

Dean, DD, Muniz, OE, Rodriquez, I, Carreno, MR, Morales, S, Agundez, A, Madan, ME, Altman, RD, Annefeld, M & Howell, DS 1991, 'Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan-peptide association complex (Rumalon)', Arthritis and Rheumatism, vol. 34, no. 3, pp. 304-313.
Dean DD, Muniz OE, Rodriquez I, Carreno MR, Morales S, Agundez A et al. Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan-peptide association complex (Rumalon). Arthritis and Rheumatism. 1991 Mar;34(3):304-313.
Dean, David D. ; Muniz, Ofelia E. ; Rodriquez, Ivette ; Carreno, Manuel R. ; Morales, Sara ; Agundez, Agueda ; Madan, Maria Elena ; Altman, Roy D ; Annefeld, Marlieseo ; Howell, David S. / Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan-peptide association complex (Rumalon). In: Arthritis and Rheumatism. 1991 ; Vol. 34, No. 3. pp. 304-313.
@article{6e218af0d0724b638ad0afd94a419e7e,
title = "Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan-peptide association complex (Rumalon)",
abstract = "The chondroprotective potential of glycosaminoglycan-peptide association complex (GP-C) was examined in the medial meniscectomy model of lapine osteoarthritis (OA). Prophylactic treatment with increasing doses of intramuscular GP-C (0.05-0.5 ml/kg) caused a significant reduction in OA lesion area and histologic scores, and the effect on disease activity appeared to be dose related. The DNA and uronic acid contents of OA tissue were unaffected by prophylactic treatment with GP-C. However, levels of hydroxyproline in OA cartilage ineased to near control levels with prophylactic treatment. Cartilage levels of active and total metalloproteinases that digest proteoglycans were elevated in rabbits with OA; prophylactic treatment with low-dose GP-C (0.05 ml/kg) produced a significant reduction in active, but not total, enzyme. Cartilage levels of tissue inhibitor of metalloproteinases in animals with OA were comparable with control levels, but rose with increasing doses of GP-C. We also investigated GP-C as a therapeutic treatment in animals that had already developed OA lesions. Carbon black retention and histologic score returned to near-normal after therapeutic treatment with GP-C. Uronic acid and hydroxyproline levels were decreased in OA cartilage. Therapeutic treatment with GP-C had no statistically significant effect on uronic acid levels, but was associated with increased hydroxyproline content in the cartilage. The changes in metalloproteinase and metalloproteinase inhibitor were similar to those found in the studies of prophylactic treatment. The findings in this animal model may help explain some of the beneficial effects of GP-C in human OA.",
author = "Dean, {David D.} and Muniz, {Ofelia E.} and Ivette Rodriquez and Carreno, {Manuel R.} and Sara Morales and Agueda Agundez and Madan, {Maria Elena} and Altman, {Roy D} and Marlieseo Annefeld and Howell, {David S.}",
year = "1991",
month = "3",
language = "English (US)",
volume = "34",
pages = "304--313",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan-peptide association complex (Rumalon)

AU - Dean, David D.

AU - Muniz, Ofelia E.

AU - Rodriquez, Ivette

AU - Carreno, Manuel R.

AU - Morales, Sara

AU - Agundez, Agueda

AU - Madan, Maria Elena

AU - Altman, Roy D

AU - Annefeld, Marlieseo

AU - Howell, David S.

PY - 1991/3

Y1 - 1991/3

N2 - The chondroprotective potential of glycosaminoglycan-peptide association complex (GP-C) was examined in the medial meniscectomy model of lapine osteoarthritis (OA). Prophylactic treatment with increasing doses of intramuscular GP-C (0.05-0.5 ml/kg) caused a significant reduction in OA lesion area and histologic scores, and the effect on disease activity appeared to be dose related. The DNA and uronic acid contents of OA tissue were unaffected by prophylactic treatment with GP-C. However, levels of hydroxyproline in OA cartilage ineased to near control levels with prophylactic treatment. Cartilage levels of active and total metalloproteinases that digest proteoglycans were elevated in rabbits with OA; prophylactic treatment with low-dose GP-C (0.05 ml/kg) produced a significant reduction in active, but not total, enzyme. Cartilage levels of tissue inhibitor of metalloproteinases in animals with OA were comparable with control levels, but rose with increasing doses of GP-C. We also investigated GP-C as a therapeutic treatment in animals that had already developed OA lesions. Carbon black retention and histologic score returned to near-normal after therapeutic treatment with GP-C. Uronic acid and hydroxyproline levels were decreased in OA cartilage. Therapeutic treatment with GP-C had no statistically significant effect on uronic acid levels, but was associated with increased hydroxyproline content in the cartilage. The changes in metalloproteinase and metalloproteinase inhibitor were similar to those found in the studies of prophylactic treatment. The findings in this animal model may help explain some of the beneficial effects of GP-C in human OA.

AB - The chondroprotective potential of glycosaminoglycan-peptide association complex (GP-C) was examined in the medial meniscectomy model of lapine osteoarthritis (OA). Prophylactic treatment with increasing doses of intramuscular GP-C (0.05-0.5 ml/kg) caused a significant reduction in OA lesion area and histologic scores, and the effect on disease activity appeared to be dose related. The DNA and uronic acid contents of OA tissue were unaffected by prophylactic treatment with GP-C. However, levels of hydroxyproline in OA cartilage ineased to near control levels with prophylactic treatment. Cartilage levels of active and total metalloproteinases that digest proteoglycans were elevated in rabbits with OA; prophylactic treatment with low-dose GP-C (0.05 ml/kg) produced a significant reduction in active, but not total, enzyme. Cartilage levels of tissue inhibitor of metalloproteinases in animals with OA were comparable with control levels, but rose with increasing doses of GP-C. We also investigated GP-C as a therapeutic treatment in animals that had already developed OA lesions. Carbon black retention and histologic score returned to near-normal after therapeutic treatment with GP-C. Uronic acid and hydroxyproline levels were decreased in OA cartilage. Therapeutic treatment with GP-C had no statistically significant effect on uronic acid levels, but was associated with increased hydroxyproline content in the cartilage. The changes in metalloproteinase and metalloproteinase inhibitor were similar to those found in the studies of prophylactic treatment. The findings in this animal model may help explain some of the beneficial effects of GP-C in human OA.

UR - http://www.scopus.com/inward/record.url?scp=0025978461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025978461&partnerID=8YFLogxK

M3 - Article

C2 - 2003855

AN - SCOPUS:0025978461

VL - 34

SP - 304

EP - 313

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 3

ER -